The global market for Pharmaceutical CDMO Solution was valued at US$ 147720 million in the year 2024 and is projected to reach a revised size of US$ 246510 million by 2031, growing at a CAGR of 7.7% during the forecast period.
Pharmaceutical CDMO (Contract Development and Manufacturing Organization) solutions refer to the services offered by companies that provide end-to-end outsourcing services to the pharmaceutical industry. CDMOs partner with pharmaceutical companies to assist in various stages of drug development, from early-stage research and development (R&D) to commercial-scale manufacturing and distribution.
The pharmaceutical Contract Development and Manufacturing Organization (CDMO) industry has experienced significant growth and transformation in recent years. CDMOs play a crucial role in supporting pharmaceutical companies by providing a wide range of services to expedite drug development and manufacturing processes. Pharmaceutical companies increasingly rely on CDMOs to access specialized expertise, advanced technologies, and cost-effective solutions, enabling them to focus on core research and marketing activities. The rising complexity of drug development, along with increasing regulatory requirements, has led to a higher demand for CDMO services, particularly in specialized areas like biologics, gene therapies, and personalized medicine. The United States and Canada are significant markets for pharmaceutical CDMOs due to a large number of biopharmaceutical companies and a robust outsourcing landscape. European countries, including the United Kingdom, Germany, and Switzerland, have a well-established pharmaceutical industry, contributing to a strong demand for CDMO services. Countries like India, China, and South Korea have emerged as major players in the CDMO market, offering cost-competitive services and advanced manufacturing capabilities. The global market for pharmaceutical CDMO solutions is expected to witness continued growth in the coming years, driven by increased outsourcing by pharmaceutical companies seeking specialized expertise, cost-effectiveness, and accelerated drug development timelines. Additionally, the ongoing advancements in biotechnology, gene therapies, and personalized medicine are likely to create new opportunities for CDMOs, as these cutting-edge areas require specialized capabilities and infrastructure.
This report aims to provide a comprehensive presentation of the global market for Pharmaceutical CDMO Solution, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmaceutical CDMO Solution.
The Pharmaceutical CDMO Solution market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Pharmaceutical CDMO Solution market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pharmaceutical CDMO Solution companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Recipharm AB
Lonza Group
Catalent
Patheon (Thermo Fisher Scientific)
Siegfried AG
SGS Quay Pharmaceuticals
Curia
Thermo Fisher Scientific
Samsung Biologics
Fujifilm Diosynth Biotechnologies
Societal CDMO
Aenova Group
Eurofins CDMO
Piramal Group
WuXi AppTec Group
Fareva
Strides Pharma Science
Famar Health Care Service
WuXi Biologics
Asymchem
Pfizer CentreOne
Segment by Type
Active Pharmaceutical Ingredient (API) Manufacturing
Finished Dosage Formulation (FDF) Development and Manufacturing
Secondary Packaging
Others
Segment by Application
Pharmaceutical Company
Biotechnology Company
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pharmaceutical CDMO Solution company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pharmaceutical CDMO Solution Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Active Pharmaceutical Ingredient (API) Manufacturing
1.2.3 Finished Dosage Formulation (FDF) Development and Manufacturing
1.2.4 Secondary Packaging
1.2.5 Others
1.3 Market by Application
1.3.1 Global Pharmaceutical CDMO Solution Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical Company
1.3.3 Biotechnology Company
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pharmaceutical CDMO Solution Market Perspective (2020-2031)
2.2 Global Pharmaceutical CDMO Solution Growth Trends by Region
2.2.1 Global Pharmaceutical CDMO Solution Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Pharmaceutical CDMO Solution Historic Market Size by Region (2020-2025)
2.2.3 Pharmaceutical CDMO Solution Forecasted Market Size by Region (2026-2031)
2.3 Pharmaceutical CDMO Solution Market Dynamics
2.3.1 Pharmaceutical CDMO Solution Industry Trends
2.3.2 Pharmaceutical CDMO Solution Market Drivers
2.3.3 Pharmaceutical CDMO Solution Market Challenges
2.3.4 Pharmaceutical CDMO Solution Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharmaceutical CDMO Solution Players by Revenue
3.1.1 Global Top Pharmaceutical CDMO Solution Players by Revenue (2020-2025)
3.1.2 Global Pharmaceutical CDMO Solution Revenue Market Share by Players (2020-2025)
3.2 Global Pharmaceutical CDMO Solution Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Pharmaceutical CDMO Solution Revenue
3.4 Global Pharmaceutical CDMO Solution Market Concentration Ratio
3.4.1 Global Pharmaceutical CDMO Solution Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmaceutical CDMO Solution Revenue in 2024
3.5 Global Key Players of Pharmaceutical CDMO Solution Head office and Area Served
3.6 Global Key Players of Pharmaceutical CDMO Solution, Product and Application
3.7 Global Key Players of Pharmaceutical CDMO Solution, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharmaceutical CDMO Solution Breakdown Data by Type
4.1 Global Pharmaceutical CDMO Solution Historic Market Size by Type (2020-2025)
4.2 Global Pharmaceutical CDMO Solution Forecasted Market Size by Type (2026-2031)
5 Pharmaceutical CDMO Solution Breakdown Data by Application
5.1 Global Pharmaceutical CDMO Solution Historic Market Size by Application (2020-2025)
5.2 Global Pharmaceutical CDMO Solution Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Pharmaceutical CDMO Solution Market Size (2020-2031)
6.2 North America Pharmaceutical CDMO Solution Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Pharmaceutical CDMO Solution Market Size by Country (2020-2025)
6.4 North America Pharmaceutical CDMO Solution Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pharmaceutical CDMO Solution Market Size (2020-2031)
7.2 Europe Pharmaceutical CDMO Solution Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Pharmaceutical CDMO Solution Market Size by Country (2020-2025)
7.4 Europe Pharmaceutical CDMO Solution Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pharmaceutical CDMO Solution Market Size (2020-2031)
8.2 Asia-Pacific Pharmaceutical CDMO Solution Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Pharmaceutical CDMO Solution Market Size by Region (2020-2025)
8.4 Asia-Pacific Pharmaceutical CDMO Solution Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pharmaceutical CDMO Solution Market Size (2020-2031)
9.2 Latin America Pharmaceutical CDMO Solution Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Pharmaceutical CDMO Solution Market Size by Country (2020-2025)
9.4 Latin America Pharmaceutical CDMO Solution Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pharmaceutical CDMO Solution Market Size (2020-2031)
10.2 Middle East & Africa Pharmaceutical CDMO Solution Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Pharmaceutical CDMO Solution Market Size by Country (2020-2025)
10.4 Middle East & Africa Pharmaceutical CDMO Solution Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Recipharm AB
11.1.1 Recipharm AB Company Details
11.1.2 Recipharm AB Business Overview
11.1.3 Recipharm AB Pharmaceutical CDMO Solution Introduction
11.1.4 Recipharm AB Revenue in Pharmaceutical CDMO Solution Business (2020-2025)
11.1.5 Recipharm AB Recent Development
11.2 Lonza Group
11.2.1 Lonza Group Company Details
11.2.2 Lonza Group Business Overview
11.2.3 Lonza Group Pharmaceutical CDMO Solution Introduction
11.2.4 Lonza Group Revenue in Pharmaceutical CDMO Solution Business (2020-2025)
11.2.5 Lonza Group Recent Development
11.3 Catalent
11.3.1 Catalent Company Details
11.3.2 Catalent Business Overview
11.3.3 Catalent Pharmaceutical CDMO Solution Introduction
11.3.4 Catalent Revenue in Pharmaceutical CDMO Solution Business (2020-2025)
11.3.5 Catalent Recent Development
11.4 Patheon (Thermo Fisher Scientific)
11.4.1 Patheon (Thermo Fisher Scientific) Company Details
11.4.2 Patheon (Thermo Fisher Scientific) Business Overview
11.4.3 Patheon (Thermo Fisher Scientific) Pharmaceutical CDMO Solution Introduction
11.4.4 Patheon (Thermo Fisher Scientific) Revenue in Pharmaceutical CDMO Solution Business (2020-2025)
11.4.5 Patheon (Thermo Fisher Scientific) Recent Development
11.5 Siegfried AG
11.5.1 Siegfried AG Company Details
11.5.2 Siegfried AG Business Overview
11.5.3 Siegfried AG Pharmaceutical CDMO Solution Introduction
11.5.4 Siegfried AG Revenue in Pharmaceutical CDMO Solution Business (2020-2025)
11.5.5 Siegfried AG Recent Development
11.6 SGS Quay Pharmaceuticals
11.6.1 SGS Quay Pharmaceuticals Company Details
11.6.2 SGS Quay Pharmaceuticals Business Overview
11.6.3 SGS Quay Pharmaceuticals Pharmaceutical CDMO Solution Introduction
11.6.4 SGS Quay Pharmaceuticals Revenue in Pharmaceutical CDMO Solution Business (2020-2025)
11.6.5 SGS Quay Pharmaceuticals Recent Development
11.7 Curia
11.7.1 Curia Company Details
11.7.2 Curia Business Overview
11.7.3 Curia Pharmaceutical CDMO Solution Introduction
11.7.4 Curia Revenue in Pharmaceutical CDMO Solution Business (2020-2025)
11.7.5 Curia Recent Development
11.8 Thermo Fisher Scientific
11.8.1 Thermo Fisher Scientific Company Details
11.8.2 Thermo Fisher Scientific Business Overview
11.8.3 Thermo Fisher Scientific Pharmaceutical CDMO Solution Introduction
11.8.4 Thermo Fisher Scientific Revenue in Pharmaceutical CDMO Solution Business (2020-2025)
11.8.5 Thermo Fisher Scientific Recent Development
11.9 Samsung Biologics
11.9.1 Samsung Biologics Company Details
11.9.2 Samsung Biologics Business Overview
11.9.3 Samsung Biologics Pharmaceutical CDMO Solution Introduction
11.9.4 Samsung Biologics Revenue in Pharmaceutical CDMO Solution Business (2020-2025)
11.9.5 Samsung Biologics Recent Development
11.10 Fujifilm Diosynth Biotechnologies
11.10.1 Fujifilm Diosynth Biotechnologies Company Details
11.10.2 Fujifilm Diosynth Biotechnologies Business Overview
11.10.3 Fujifilm Diosynth Biotechnologies Pharmaceutical CDMO Solution Introduction
11.10.4 Fujifilm Diosynth Biotechnologies Revenue in Pharmaceutical CDMO Solution Business (2020-2025)
11.10.5 Fujifilm Diosynth Biotechnologies Recent Development
11.11 Societal CDMO
11.11.1 Societal CDMO Company Details
11.11.2 Societal CDMO Business Overview
11.11.3 Societal CDMO Pharmaceutical CDMO Solution Introduction
11.11.4 Societal CDMO Revenue in Pharmaceutical CDMO Solution Business (2020-2025)
11.11.5 Societal CDMO Recent Development
11.12 Aenova Group
11.12.1 Aenova Group Company Details
11.12.2 Aenova Group Business Overview
11.12.3 Aenova Group Pharmaceutical CDMO Solution Introduction
11.12.4 Aenova Group Revenue in Pharmaceutical CDMO Solution Business (2020-2025)
11.12.5 Aenova Group Recent Development
11.13 Eurofins CDMO
11.13.1 Eurofins CDMO Company Details
11.13.2 Eurofins CDMO Business Overview
11.13.3 Eurofins CDMO Pharmaceutical CDMO Solution Introduction
11.13.4 Eurofins CDMO Revenue in Pharmaceutical CDMO Solution Business (2020-2025)
11.13.5 Eurofins CDMO Recent Development
11.14 Piramal Group
11.14.1 Piramal Group Company Details
11.14.2 Piramal Group Business Overview
11.14.3 Piramal Group Pharmaceutical CDMO Solution Introduction
11.14.4 Piramal Group Revenue in Pharmaceutical CDMO Solution Business (2020-2025)
11.14.5 Piramal Group Recent Development
11.15 WuXi AppTec Group
11.15.1 WuXi AppTec Group Company Details
11.15.2 WuXi AppTec Group Business Overview
11.15.3 WuXi AppTec Group Pharmaceutical CDMO Solution Introduction
11.15.4 WuXi AppTec Group Revenue in Pharmaceutical CDMO Solution Business (2020-2025)
11.15.5 WuXi AppTec Group Recent Development
11.16 Fareva
11.16.1 Fareva Company Details
11.16.2 Fareva Business Overview
11.16.3 Fareva Pharmaceutical CDMO Solution Introduction
11.16.4 Fareva Revenue in Pharmaceutical CDMO Solution Business (2020-2025)
11.16.5 Fareva Recent Development
11.17 Strides Pharma Science
11.17.1 Strides Pharma Science Company Details
11.17.2 Strides Pharma Science Business Overview
11.17.3 Strides Pharma Science Pharmaceutical CDMO Solution Introduction
11.17.4 Strides Pharma Science Revenue in Pharmaceutical CDMO Solution Business (2020-2025)
11.17.5 Strides Pharma Science Recent Development
11.18 Famar Health Care Service
11.18.1 Famar Health Care Service Company Details
11.18.2 Famar Health Care Service Business Overview
11.18.3 Famar Health Care Service Pharmaceutical CDMO Solution Introduction
11.18.4 Famar Health Care Service Revenue in Pharmaceutical CDMO Solution Business (2020-2025)
11.18.5 Famar Health Care Service Recent Development
11.19 WuXi Biologics
11.19.1 WuXi Biologics Company Details
11.19.2 WuXi Biologics Business Overview
11.19.3 WuXi Biologics Pharmaceutical CDMO Solution Introduction
11.19.4 WuXi Biologics Revenue in Pharmaceutical CDMO Solution Business (2020-2025)
11.19.5 WuXi Biologics Recent Development
11.20 Asymchem
11.20.1 Asymchem Company Details
11.20.2 Asymchem Business Overview
11.20.3 Asymchem Pharmaceutical CDMO Solution Introduction
11.20.4 Asymchem Revenue in Pharmaceutical CDMO Solution Business (2020-2025)
11.20.5 Asymchem Recent Development
11.21 Pfizer CentreOne
11.21.1 Pfizer CentreOne Company Details
11.21.2 Pfizer CentreOne Business Overview
11.21.3 Pfizer CentreOne Pharmaceutical CDMO Solution Introduction
11.21.4 Pfizer CentreOne Revenue in Pharmaceutical CDMO Solution Business (2020-2025)
11.21.5 Pfizer CentreOne Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
Recipharm AB
Lonza Group
Catalent
Patheon (Thermo Fisher Scientific)
Siegfried AG
SGS Quay Pharmaceuticals
Curia
Thermo Fisher Scientific
Samsung Biologics
Fujifilm Diosynth Biotechnologies
Societal CDMO
Aenova Group
Eurofins CDMO
Piramal Group
WuXi AppTec Group
Fareva
Strides Pharma Science
Famar Health Care Service
WuXi Biologics
Asymchem
Pfizer CentreOne
听
听
*If Applicable.
